Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Azithromycin on Acumapimod Exposure
NCT02926326Phase 1Completed
- Sponsor
- Mereo BioPharma
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acumapimod in chronic obstructive pulmonary disease (COPD), sponsored by Mereo BioPharma. Primary endpoints: Maximum Measurable Plasma Concentration and Area Under the Plasma Concentration-Time Curve. Started Sep 2016; status: completed.
02
Drugs
acumapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02926326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926326.